D. Hasmono, Samirah Samirah, R. Hartono, M. Subkhan, Maria Angelia Yoshida, Fenny Kesuma Leliga
{"title":"Remdesivir 用于治疗印度尼西亚 COVID-19 住院患者的安全性结果","authors":"D. Hasmono, Samirah Samirah, R. Hartono, M. Subkhan, Maria Angelia Yoshida, Fenny Kesuma Leliga","doi":"10.46542/pe.2024.243.348352","DOIUrl":null,"url":null,"abstract":"Background: Remdesivir has been granted emergency use authorisation for hospitalised COVID-19 patients. However, the available evidence in Indonesia is limited to related liver and kidney injuries.\nObjective: This study aims to assess the safety of remdesivir based on liver and kidney function and its association with comorbidity and disease severity.\nMethod: This retrospective study evaluated remdesivir's efficacy in hospitalised COVID-19 patients of varying severity by collecting baseline and follow-up data on aspartate aminotransferase (AST), alanine aminotransferase (ALT), Glomerular filtration rate (GFR) and Blood urea nitrogen (BUN).\nResult: In this study, 189 patients with elevated transaminase enzyme levels were given hepatoprotection therapy. Patients who did not receive the treatment experienced a significant rise in ALT levels (p < 0.001), while BUN levels increased significantly (p = 0.001) but within the normal range. There was no worsening of GFR value (p < 0.001), and no significant association was found between AST and ALT levels with comorbidity and disease severity (p < 0.001; OR 50.202).\nConclusion: Remdesivir demonstrated good tolerability despite increased ALT and BUN without correlating to comorbidity or disease severity in COVID-19.","PeriodicalId":0,"journal":{"name":"","volume":"5 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety outcomes of remdesivir for treatment of COVID-19 hospitalised patients in Indonesia\",\"authors\":\"D. Hasmono, Samirah Samirah, R. Hartono, M. Subkhan, Maria Angelia Yoshida, Fenny Kesuma Leliga\",\"doi\":\"10.46542/pe.2024.243.348352\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Remdesivir has been granted emergency use authorisation for hospitalised COVID-19 patients. However, the available evidence in Indonesia is limited to related liver and kidney injuries.\\nObjective: This study aims to assess the safety of remdesivir based on liver and kidney function and its association with comorbidity and disease severity.\\nMethod: This retrospective study evaluated remdesivir's efficacy in hospitalised COVID-19 patients of varying severity by collecting baseline and follow-up data on aspartate aminotransferase (AST), alanine aminotransferase (ALT), Glomerular filtration rate (GFR) and Blood urea nitrogen (BUN).\\nResult: In this study, 189 patients with elevated transaminase enzyme levels were given hepatoprotection therapy. Patients who did not receive the treatment experienced a significant rise in ALT levels (p < 0.001), while BUN levels increased significantly (p = 0.001) but within the normal range. There was no worsening of GFR value (p < 0.001), and no significant association was found between AST and ALT levels with comorbidity and disease severity (p < 0.001; OR 50.202).\\nConclusion: Remdesivir demonstrated good tolerability despite increased ALT and BUN without correlating to comorbidity or disease severity in COVID-19.\",\"PeriodicalId\":0,\"journal\":{\"name\":\"\",\"volume\":\"5 6\",\"pages\":\"\"},\"PeriodicalIF\":0.0,\"publicationDate\":\"2024-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.46542/pe.2024.243.348352\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46542/pe.2024.243.348352","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Safety outcomes of remdesivir for treatment of COVID-19 hospitalised patients in Indonesia
Background: Remdesivir has been granted emergency use authorisation for hospitalised COVID-19 patients. However, the available evidence in Indonesia is limited to related liver and kidney injuries.
Objective: This study aims to assess the safety of remdesivir based on liver and kidney function and its association with comorbidity and disease severity.
Method: This retrospective study evaluated remdesivir's efficacy in hospitalised COVID-19 patients of varying severity by collecting baseline and follow-up data on aspartate aminotransferase (AST), alanine aminotransferase (ALT), Glomerular filtration rate (GFR) and Blood urea nitrogen (BUN).
Result: In this study, 189 patients with elevated transaminase enzyme levels were given hepatoprotection therapy. Patients who did not receive the treatment experienced a significant rise in ALT levels (p < 0.001), while BUN levels increased significantly (p = 0.001) but within the normal range. There was no worsening of GFR value (p < 0.001), and no significant association was found between AST and ALT levels with comorbidity and disease severity (p < 0.001; OR 50.202).
Conclusion: Remdesivir demonstrated good tolerability despite increased ALT and BUN without correlating to comorbidity or disease severity in COVID-19.